Abstract: A variable transmittance optical stack, a manufacturing method therefor, a smart window including the same, and windows for an automobile or a building using the same are proposed.

Abstract: A variable transmittance optical stack a manufacturing method therefor, a smart window including the same, and windows for an automobile or a building using the same are proposed.

Abstract: A variable transmittance optical stack, a manufacturing method therefor, a smart window including the same, and windows for an automobile or a building using the same are proposed.

Abstract: There is provided a method for forming fine patterns. The method includes forming a pattern divider on an underlying layer, forming a mask layer on the underlying layer to cover the pattern divider, forming an opening pattern that vertically penetrates the mask layer to expose a portion of the pattern divider and intersects the exposed portion of the pattern divider, and selectively removing portions of the underlying layer exposed by the opening pattern of the mask layer to form a couple of opening sub-patterns.

Abstract: There is provided a method for forming fine patterns. The method includes forming a pattern divider on an underlying layer, forming a mask layer on the underlying layer to cover the pattern divider, forming an opening pattern that vertically penetrates the mask layer to expose a portion of the pattern divider and intersects the exposed portion of the pattern divider, and selectively removing portions of the underlying layer exposed by the opening pattern of the mask layer to form a couple of opening sub-patterns.

Abstract: The present invention relates to a pharmaceutical composition for treating or preventing a disease related to abnormal suppression of regulatory T cell activity comprising a polypeptide comprising a bee venom-PLA2 amino acid sequence exclusive of a leader sequence as an active ingredient. The secretory bee venom-phospholipase A2 of the present invention activates a regulatory T cell and suppress a differentiation of Th1/Th7. Therefore, the present polypeptide can be used as a pharmaceutical composition for treating or preventing a disease related to abnormal suppression of regulatory T cell activity, i.e. autoimmune diseases, allergic diseases, or neurodegenerative diseases.

Abstract: The present invention relates to a pharmaceutical composition for treating or preventing a disease related to abnormal suppression of regulatory T cell activity comprising a polypeptide comprising a bee venom-PLA2 amino acid sequence exclusive of a leader sequence as an active ingredient. The secretory bee venom-phospholipase A2 of the present invention activates a regulatory T cell and suppress a differentiation of Th1/Th7. Therefore, the present polypeptide can be used as a pharmaceutical composition for treating or preventing a disease related to abnormal suppression of regulatory T cell activity, i.e. autoimmune diseases, allergic diseases, or neurodegenerative diseases.

Abstract: Disclosed is an uninterruptible power supply system, including a sub power supply device configured to supply or cut off sub input power to a load device; a battery configured to supply or cut off battery input power to the load device; and an uninterruptible power supply device that is electrically connected to the sub power supply device and the battery, and when main input power is selectively received and supplied to the load device or the battery input power is selectively received and supplied to the load device, determines whether the main input power and the battery input power are within a predetermined reference main input power range and reference battery input power range, and when the main input power and the battery input power are outside of the reference main input power range and the reference battery input power range, receives the sub input power and supplies the power to the load device.

Abstract: The present invention relates to a pharmaceutical composition for treating or preventing a disease related to abnormal suppression of regulatory T cell activity comprising a polypeptide comprising a bee venom-PLA2 amino acid sequence exclusive of a leader sequence as an active ingredient. The secretory bee venom-phospholipase A2 of the present invention activates a regulatory T cell and suppress a differentiation of Th1/Th7. Therefore, the present polypeptide can be used as a pharmaceutical composition for treating or preventing a disease related to abnormal suppression of regulatory T cell activity, i.e. autoimmune diseases, allergic diseases, or neurodegenerative diseases.

Abstract: The present invention relates to a pharmaceutical composition for treating or preventing a disease related to abnormal suppression of regulatory T cell activity comprising a polypeptide comprising a bee venom-PLA2 amino acid sequence exclusive of a leader sequence as an active ingredient. The secretory bee venom-phospholipase A2 of the present invention activates a regulatory T cell and suppress a differentiation of Th1/Th7. Therefore, the present polypeptide can be used as a pharmaceutical composition for treating or preventing a disease related to abnormal suppression of regulatory T cell activity, i.e. autoimmune diseases, allergic diseases, or neurodegenerative diseases.

Abstract: An oxygen concentrating apparatus includes: at least one adsorption bed which is filled with absorbent capable of selectively adsorbing nitrogen relative to oxygen; an air supplier which supplies pressurized air to the adsorption bed; a flow channel regulating valve unit which regulates flow channels by allowing the pressurized air to be supplied to the adsorption bed from the air supplier and by allowing the air to be discharged from the adsorption bed to be depressurized such that a nitrogen adsorption process and a nitrogen desorption process are alternately performed; and a water removing unit which separates water from the pressurized air supplied from the air supplier and removes the separated water. The flow channel regulating unit and the water removing unit are at least partially housed within a single housing.

Abstract: An oxygen concentrating apparatus includes: at least one adsorption bed which is filled with absorbent capable of selectively adsorbing nitrogen relative to oxygen; an air supplier which supplies pressurized air to the adsorption bed; a flow channel regulating valve unit which regulates flow channels by allowing the pressurized air to be supplied to the adsorption bed from the air supplier and by allowing the air to be discharged from the adsorption bed to be depressurized such that a nitrogen adsorption process and a nitrogen desorption process are alternately performed; and a water removing unit which separates water from the pressurized air supplied from the air supplier and removes the separated water. The flow channel regulating unit and the water removing unit are at least partially housed within a single housing.

Abstract: The present invention relates to a pharmaceutical composition for treating or preventing a disease related to abnormal suppression of regulatory T cell activity comprising a polypeptide comprising a bee venom-PLA2 amino acid sequence exclusive of a leader sequence as an active ingredient. The secretory bee venom-phospholipase A2 of the present invention activates a regulatory T cell and suppress a differentiation of Th1/Th7. Therefore, the present polypeptide can be used as a pharmaceutical composition for treating or preventing a disease related to abnormal suppression of regulatory T cell activity, i.e. autoimmune diseases, allergic diseases, or neurodegenerative diseases.

Abstract: Disclosed is an uninterruptible power supply system, including a sub power supply device configured to supply or cut off sub input power to a load device; a battery configured to supply or cut off battery input power to the load device; and an uninterruptible power supply device that is electrically connected to the sub power supply device and the battery, and when main input power is selectively received and supplied to the load device or the battery input power is selectively received and supplied to the load device, determines whether the main input power and the battery input power are within a predetermined reference main input power range and reference battery input power range, and when the main input power and the battery input power are outside of the reference main input power range and the reference battery input power range, receives the sub input power and supplies the power to the load device.

Abstract: The present invention relates to a pharmaceutical composition for treating or preventing a disease related to abnormal suppression of regulatory T cell activity comprising a polypeptide comprising a bee venom-PLA2 amino acid sequence exclusive of a leader sequence as an active ingredient. The secretory bee venom-phospholipase A2 of the present invention activates a regulatory T cell and suppress a differentiation of Th1/Th7. Therefore, the present polypeptide can be used as a pharmaceutical composition for treating or preventing a disease related to abnormal suppression of regulatory T cell activity, i.e. autoimmune diseases, allergic diseases, or neurodegenerative diseases.